- Series B
Siolta Therapeutics is a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics for the prevention and treatment of inflammatory, chronic, and life-threatening diseases. STMC-103H, currently in Phase 1b/2 development in the US, is designed to trigger tolerant immunological development and prevent the onset of allergic disease in at-risk infant population. The company has successfully manufactured multi-strain drug product, completed a “first-in-human” clinical trial establishing safety in children and adults, and received Fast Track Designation from the FDA for its lead program. By leveraging its proprietary technology platform, the company is evaluating multiple live biotherapeutic product candidates for future development.